GT Biopharma, Inc. financial data

Symbol
GTBP on Nasdaq
Location
505 Montgomery Street, 10 Th Floor, San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 126 % -48.7%
Debt-to-equity 68.8 % +49.2%
Return On Assets -175 % -293%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.56M shares +59.2%
Common Stock, Shares, Outstanding 3.27M shares +46.5%
Entity Public Float 5.1M USD -55.7%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 2.77M shares +61.9%
Weighted Average Number of Shares Outstanding, Diluted 2.77M shares +61.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.7M USD -11%
Operating Income (Loss) -10.8M USD +18.6%
Nonoperating Income (Expense) 1.42M USD -26.7%
Net Income (Loss) Attributable to Parent -9.4M USD +17.3%
Earnings Per Share, Basic -4 USD/shares +48.3%
Earnings Per Share, Diluted -4 USD/shares +48.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.23M USD -43.5%
Cash, Cash Equivalents, and Short-term Investments 9.2M USD -48.9%
Assets, Current 7.12M USD -23.1%
Operating Lease, Right-of-Use Asset 27K USD -80.7%
Assets 4.23M USD -70%
Accounts Payable, Current 1.37M USD -20%
Accrued Liabilities, Current 608K USD -65.6%
Liabilities, Current 2.31M USD -38.6%
Operating Lease, Liability, Noncurrent 31K USD -78.9%
Liabilities 4.6M USD -34.6%
Retained Earnings (Accumulated Deficit) -698M USD -1.38%
Stockholders' Equity Attributable to Parent 2.86M USD -48.1%
Liabilities and Equity 7.12M USD -23.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.2M USD +47.1%
Net Cash Provided by (Used in) Financing Activities 616K USD
Net Cash Provided by (Used in) Investing Activities 5.03K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 3.27M shares +46.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.59M USD -282%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.32M USD -42.5%
Deferred Tax Assets, Valuation Allowance 112M USD +2.27%
Deferred Tax Assets, Gross 112M USD +2.27%
Operating Lease, Liability 30K USD -80.9%
Lessee, Operating Lease, Liability, to be Paid 30K USD -79.6%
Operating Lease, Liability, Current 30K USD -74.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 60M USD +49080%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Preferred Stock, Shares Issued 96.2K shares
Preferred Stock, Shares Authorized 15M shares 0%
Additional Paid in Capital 700M USD +0.99%
Preferred Stock, Shares Outstanding 96.2K shares
Interest Expense 212K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%